News & Updates

Achieving low-risk status in PAH with prostacyclin receptor agonist–based triple therapy

A 72-year-old female with a history of well-controlled hypertension presented with unexplained dyspnoea and reduced exercise tolerance for the past 2–3 years.

Simplified questionnaire aims to improve early PN diagnosis

Early recognition of peripheral neuropathy (PN) is crucial to prevent or delay disease progression and development of associated complications. In an interview with MIMS Doctor, Dr Vivien Lim, Specialist in Endocrinology at the Gleneagles Medical Centre in Singapore, discussed potential reasons for delayed PN diagnosis, particularly in patients with diabetes mellitus (DM). She also introduced a simple questionnaire developed by a panel of neurologists and endocrinologists for both patients and physicians, to urge early detection of PN in the primary care setting.

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ARASENS post hoc sensitivity analysis data presented at ASCO GU 2024 support primary OS analysis and demonstrate that darolutamide + ADT + docetaxel is an effective, well-tolerated SoC for mHSPC. 

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer held in San Diego, US, researchers presented updated results from the two-part, phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) associated with dostarlimab-based combinations in patients with primary advanced or recurrent endometrial cancer (EC).

Optimizing first-and subsequent-line therapy for advanced RCC

The treatment landscape of metastatic renal cell carcinoma (mRCC) has undergone a major transformation in the past two decades, with interleukin-2 and interferon-α being replaced with anti-angiogenic tyrosine kinase inhibitors (TKIs), inhibitors of mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors (ICIs). At an Eisai-sponsored symposium organized by the Hong Kong Society of Uro-Oncology during Uro-Oncology Asia 2024, Professor Sun-Young Rha of the Yonsei University College of Medicine in Seoul, South Korea, discussed the importance of optimizing first-line treatment and subsequent strategies for patients with advanced RCC. Rha also reviewed clinical evidence on regimens containing lenvatinib (Lenvima^®, Eisai), an oral TKI against VEGF receptor, which have been shown to improve outcomes in first and subsequent lines of therapy.

Use of an anti-CD38 mAb in a transplant-ineligible patient with newly diagnosed multiple myeloma

A 66-year-old man with plasma cell myeloma and high-risk cytogenetic abnormality was referred to our centre in September 2022. He previously visited a private clinic in August 2022 for back and rib pain, where he received his earlier diagnosis. He was a smoker and chronic drinker with a history of hypertension. His Eastern Cooperative Oncology Group performance status (ECOG PS) was 0–1.

DUO-E: Durvalumab combo ups survival in advanced endometrial cancer, including in pMMR patients

At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, Professor Jean-François Baurain of the Cliniques Universitaires Saint-Luc in Brussels, Belgium, and Dr Hye-Sook Chon of the H. Lee Moffitt Cancer Center in Tampa, Florida, US, shared positive updates from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial (DUO-E), which demonstrated survival benefits associated with adding the immune checkpoint inhibitor, durvalumab, with or without the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, to standard platinum-based chemotherapy in patients with advanced endometrial cancer, including those with mismatch repair–proficient (pMMR) tumours.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins